AVXL

Over the past six months, Anavex Life Sciences Corp.'s stock price has experienced a significant decline, with a 52-week range between $2.61 and $13.99, and a change of -60.970% over the past year. In March 2026, Anavex withdrew its application for blarcamesine in the EU for early Alzheimer's disease. In May 2026, Terrie Kellmeyer was appointed as interim CEO, succeeding Christopher Missling. The company reported quarterly earnings data, including ($0.06) earnings per share (EPS) for the quarter ending February 9, 2026, surpassing analysts' consensus estimates of ($0.10). Rodman & Renshaw initiated coverage with a "buy" rating and a $20.00 price target in May 2026.